Table 2.
Name of Study | Status | Condition | Intervention |
---|---|---|---|
Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma | Active, Not recruiting | Mantle Cell Lymphoma | Bortezomib, Rituximab, Cyclophosphamide, Vincristine, Methotrexate, Cytarabine, Doxorubicin |
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma | Active, Not recruiting | Mantle Cell Lymphoma | EPOCH, Rituximab, Bortezomib |
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma | Active, Not recruiting | Mantle Cell Lymphoma | Rituximab, Bortezomib, Lenalidomide |
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma | Recruiting | Mantle Cell Lymphoma | Ibrutinib, Bortezomib |
Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10–011) | Recruiting | Mantle Cell Lymphoma | Cladribine, Rituximab, Bortezomib |
Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma | Not Yet Recruiting | Mantle Cell Lymphoma | Bortezomib, Cytarabine, Dexamethasone, Pegfilgrastim |
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | Active, Not recruiting | Mantle Cell Lymphoma | Bortezomib, Lenalidomide |
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma | Active, Not recruiting | Lymphoma, mantle cell lymphoma, indolent lymphoma, SLL | Cladribine, Rituximab, Bortezomib |
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma | Recruiting | Recurrent and refractory B-cell non-Hodgkin Lymphoma, recurrent and refractory mantle cell lymphoma | Alisertib, Rituximab, Bortezomib |
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma | Active, Not recruiting | Recurrent adult diffuse large cell lymphoma, recurrent mantle cell lymphoma | Vorinostat, Bortezomib |
Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL | Recruiting | Mantle cell lymphoma | Rituximab, high dose Ara-C, Dexamethasone, Bortezomib |
Data obtained from clinicaltrials.gov